Olema Oncology price target raised to $43 from $30 at Jefferies

Jefferies analyst Michael Yee raised the firm’s price target on Olema Oncology (OLMA) to $43 from $30 and keeps a Buy rating on the shares. The firm says Olema is seeing more strength today on detailed data from Roche’s (RHHBY) giredestrant Phase 3 lidERA in adjuvant breast cancer. The superior benefit of next-generation oral selective estrogen receptor degrader over standard endocrine therapy continues to validate the class and offers a positive read-through for first-line trials to derisk $10B-plus opportunity for the class. Investor enthusiasm is now picking up ahead of Roche’s Phase 3 persevERA data in Q1 2026 and Olema’s Phase 3 data in the second half of 2026, Jefferies adds.